Less Ads, More Data, More Tools Register for FREE

Pin to quick picksKrm22 Plc Regulatory News (KRM)

Share Price Information for Krm22 Plc (KRM)

Share Price is delayed by 15 minutes
Get Live Data
32.50    0.00 (0.00%)
Bid:
32.00
Ask:
33.00
Spread: 1.00 (3.125%)
Market Cap: £19.28m
KRM Live PriceLast checked at - London Stock Exchange

Intraday Krm22 Plc Share Chart

Trading Update

22 Jan 2025 07:00

RNS Number : 1752U
KRM22 PLC
22 January 2025
 

KRM22 plc

("KRM22", the "Group" or the "Company")

Trading Update

 

KRM22 plc, (AIM: KRM) the technology and software investment company with a particular focus on risk management in capital markets, today issues the following trading update for the 12 month period ended 31 December 2024 ("FY2024") with total revenue, Annual Recurring Revenue ("ARR") and adjusted EBITDA all slightly ahead of management's expectations.

 

The Company expects to report audited results for FY2024 in May 2025, and is pleased to report the following financial highlights*:

 

· ARR at 31 December 2024 of £6.6m (FY2023: £5.4m) - growth of 22.2%

New contracted ARR in the year of £1.7m (FY2023: £1.1m)

£1.2m of new contracted ARR generated from direct sales and £0.5m through the relationship with Trading Technologies International, Inc,

· Total revenue recognised of approximately £6.7m (FY2023: £5.3m) - growth of 26.4%

· Adjusted EBITDA: £0.9m (FY2023: loss of £1.4m)

· Gross cash as of 31 December 2024 of £1.0m (FY2023: £0.9m)

· Net debt at 31 December 2024 of £3.5m with the Company having drawn down a total of £4.5m on the debt facility with £0.5m remaining undrawn.

 

The Company has continued to execute on its plan to increase its ARR, delivering £6.6m ARR at FY2024, a net increase of £1.2m from £5.4m at the end of FY2023 and, as at the date of this announcement, the Company's ARR has further increased to £6.8m (£6.7m at FY2024 constant FX rates), with uplifts in contractual ARR from existing customers. The Company now has 44 institutional customers using its applications, of which seven customers have contracts in place for multiple applications.

 

The cost savings plan announced in the February 2024 trading update, with annual cost savings of approximately £1.2m, together with management continuing to tightly manage the cost base of the business and some additional non-recurring revenue has contributed to the Company reporting an adjusted EBITDA profit for FY2024 of £0.9m. 

 

The growth in ARR, continued management of the underlying cost base of the business and the Company's cash balance of £1.0m, together with the availability of £0.5m, which remains undrawn, under the TT convertible loan, means that the Company expects to continue to operate within its existing cash and debt facilities. 

 

Dan Carter, CEO commented: "The continued growth in ARR to £6.6m, surpassing management's expectations of 20% year on year growth, underscores KRM22's progress towards becoming a £10.0m ARR and cash profitable business. The sales pipeline of new opportunities remains strong, and we look forward to converting these opportunities in line with our expectations for 2025."

 

\* The financial expectations noted above are preliminary, and subject to year-end financial close and audit review processes.

 

 

For further information please contact:

 

KRM22 plc

Garry Jones, Chairman

Dan Carter, CEO

Kim Suter, CFO

 

InvestorRelations@krm22.com

Cavendish Capital Markets Limited (Nominated Adviser and Sole Broker)

Carl Holmes / Isaac Hooper / Rory Sale (Corporate Finance)

Sunila de Silva (ECM)

 

+44 (0)20 7220 0500

 

 

The information contained within this announcement was deemed by the Company to constitute inside information as stipulated under the Market Abuse Regulations (EU) No. 596/2014 as it forms part of UK domestic law by virtue of the European Union (Withdrawal) Act 2018 as amended. With the publication of this announcement via a Regulatory Information Service, this inside information is now considered to be in the public domain.

 

 

About KRM22 plc

KRM22 is a closed-ended investment company which listed on AIM on 30 April 2018. The Company has been established with the objective of creating value for its investors through the investment in, and subsequent growth and development of, target companies in the technology and software sector, with a focus on risk management in capital markets.

 

Through its investments and the Global Risk Platform, KRM22 helps capital market companies reduce the cost and complexity of risk management. The Global Risk Platform provides applications to help address firms' trading and corporate risk challenges and to manage their entire enterprise risk profile.

 

Capital markets companies' partner with KRM22 to optimise risk management systems and processes, improving profitability and expanding opportunities to increase portfolio returns by leveraging risk as alpha.

 

KRM22 plc is listed on AIM and the Group is headquartered in London, with offices in several of the world's major financial centres.

 

See more about KRM22 at KRM22.com

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
TSTSELFMFEISELF
Date   Source Headline
26th May 20263:24 pmRNSHolding(s) in Company
26th May 20262:25 pmRNSHolding(s) in Company
22nd May 20267:00 amRNSDirector Dealings
20th May 202611:19 amRNSDirector Dealings
20th May 20267:00 amRNSNotice of AGM and Posting of Annual Report
13th May 20267:00 amRNSFinal Results
29th Jan 20267:00 amRNSTrading Update
7th Jan 20267:00 amRNSAppointment of Director
20th Nov 20254:12 pmRNSTR-1
11th Nov 20257:00 amRNSIssue of Equity
10th Nov 20259:28 amRNSHolding(s) in Company
5th Nov 20251:05 pmRNSResult of GM
15th Oct 20257:00 amRNSResult of Placing
14th Oct 20254:50 pmRNSProposed Placing and Subscription
17th Sep 20257:00 amRNSInterim Results
7th Aug 20257:00 amRNSTrading Update
21st Jul 20257:00 amRNSIssue of Equity
27th Jun 20252:10 pmRNSResult of AGM
6th Jun 20257:00 amRNSDirector Dealing
2nd Jun 20257:00 amRNSIssue of Restricted Stock Units
30th May 20257:00 amRNSNotice of AGM and Posting of Annual Report
21st May 20257:00 amRNSDirector Dealing
19th May 20257:00 amRNSFinal Results
29th Apr 20257:00 amRNSFacility Amendment
7th Apr 20257:00 amRNSNew Customer Contracts
1st Apr 20257:00 amRNSFacility Amendment
18th Mar 20257:00 amRNSIssue of Equity
4th Mar 20257:00 amRNSNew Customer Contract
13th Feb 20255:00 pmRNSDirector Dealing
22nd Jan 20257:00 amRNSTrading Update
10th Jan 20257:00 amRNSIssue of Equity
23rd Dec 20247:00 amRNSLoan Facility Amendment
15th Oct 20247:00 amRNSIssue of Equity
25th Sep 20247:00 amRNSInterim Results
3rd Sep 20247:00 amRNSChange of Registered Office
29th Aug 20247:00 amRNSNew Customer Contract
22nd Aug 202410:00 amRNSGrant of Options and Director/PDMR Shareholding
19th Aug 20247:00 amRNSIssue of Equity
18th Jul 20247:00 amRNSHalf Year Trading Update
21st Jun 202412:49 pmRNSResult of AGM
29th May 20247:00 amRNSNotice of AGM and Posting of Annual Report
22nd May 20247:00 amRNSFinal Results
16th Apr 20247:00 amRNSDirector Dealings
15th Apr 20247:00 amRNSNew Customer Contract
10th Apr 20247:00 amRNSIssue of Equity
7th Mar 20247:00 amRNSBoard Changes
21st Feb 20247:00 amRNSTrading Update
1st Dec 20237:00 amRNSIssue of Restricted Stock Units
26th Sep 20237:00 amRNSInterim Results
27th Jul 202311:48 amRNSResult of General Meeting

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.